Infant and Toddler Peanut Oral Immunotherapy: Initiation Before Age 2 Increases Ad Libitum Peanut Consumption
The Journal of Allergy and Clinical Immunology: In Practice · 2025-04 · 13 (4) · 885-892
DOI: 10.1016/j.jaip.2025.01.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025-04. Verfasst von S Shahzad Mustafa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Rochester Regional Health, Rochester, NY; Division of Allergy, Immunology,…. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Arachis, Desensitization, Immunologic, Allergens. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Peanut oral immunotherapy (POIT) has promising potential of disease modification, but there are no studies to date evaluating high-dose POIT, leading to ad libitum (ad lib) consumption of peanut products, especially in children 6 months to 4 years of age. OBJECTIVE: To report real-world outcomes of high-dose POIT in children 6 months to 4 years of age, including adverse events, achievement of ad lib consumption, and the impact of age on these outcome measures. METHODS: Patients 6 months to 4 years of age with a diagnosis of peanut allergy were enrolled in a POIT protocol with a goal dose of 3000 mg. Demographics along with POIT and clinical outcomes 6 months after POIT are reported. RESULTS: Sixty children, with a median age of 16 months, started POIT. Three (5%) were lost to follow-up, and 6 (10%) discontinued POIT because of recurrent adverse events or the inability to consume daily peanut protein. Fifty-one (85%) children completed POIT in a median of 7 months and were consuming ad lib peanut products for a duration of 6 months after completion of the POIT protocol. Sixteen (26.7%) children experienced a total of 22 adverse reactions during POIT. Initiating POIT before 24 months of age increased the likelihood of ad lib peanut consumption by an odds ratio of 11.69 (1.19-114.31, P = .035). CONCLUSIONS: Our study demonstrates that high-dose POIT in infants and toddlers is well tolerated and can lead to ad lib introduction of dietary peanut products into the diet, especially if initiated before 2 years of age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Rochester Regional Health, Rochester, NY; Division of Allergy, Immunology, and Rheumatology, Department of Medicine, University of Rochester Sch…
- Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Rochester Regional Health, Rochester, NY.
- Department of Anesthesia, Baylor College of Medicine, Houston, Texas; Department of Anesthesia, University of Houston Tilman J. Fertitta Family College of Medicine, Houston, Texas.
Zitieren
APA
Mustafa, S. S., Capucilli, P., Tuong, L. A., Sanchez-Tejera, D., Vadamalai, K., & Ramsey, A. (2025). Infant and Toddler Peanut Oral Immunotherapy: Initiation Before Age 2 Increases Ad Libitum Peanut Consumption. The Journal of Allergy and Clinical Immunology: In Practice, 13(4), 885-892. https://doi.org/10.1016/j.jaip.2025.01.032
Vancouver
Mustafa SS, Capucilli P, Tuong LA, Sanchez-Tejera D, Vadamalai K, Ramsey A. Infant and Toddler Peanut Oral Immunotherapy: Initiation Before Age 2 Increases Ad Libitum Peanut Consumption. The Journal of Allergy and Clinical Immunology: In Practice. 2025;13(4):885-892. doi:10.1016/j.jaip.2025.01.032
BibTeX
@article{Mustafa2025,
author = {Mustafa, S Shahzad and Capucilli, Peter and Tuong, Linh-An and Sanchez-Tejera, Denise and Vadamalai, Karthik and Ramsey, Allison},
title = {Infant and Toddler Peanut Oral Immunotherapy: Initiation Before Age 2 Increases Ad Libitum Peanut Consumption},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2025},
volume = {13},
number = {4},
pages = {885--892},
doi = {10.1016/j.jaip.2025.01.032}
}
EUVIMED